Cargando…

Reply to "A limitation regarding the association between intranasal corticosteroid use and better COVID-19 outcomes: Nasal symptoms matter"

Detalles Bibliográficos
Autores principales:	Strauss, Ronald, Attaway, Amy H., Zein, Joe G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Academy of Allergy, Asthma & Immunology 2022
Materias:	Correspondence and Reply
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733312/ https://www.ncbi.nlm.nih.gov/pubmed/35000738 http://dx.doi.org/10.1016/j.jaip.2021.10.062

Ejemplares similares

A limitation regarding the association between intranasal corticosteroid use and better COVID-19 outcomes: Nasal symptoms matter
por: Maeda, Yohei, et al.
Publicado: (2022)

Intranasal Corticosteroids Are Associated with Better Outcomes in Coronavirus Disease 2019
por: Strauss, Ronald, et al.
Publicado: (2021)

Reply to “Different effect of inhaled and systemic corticosteroids on the outcome of COVID-19 among patients with asthma”
por: Feng, Lan, et al.
Publicado: (2022)

Reply to “Variability of eliciting thresholds in PEG allergy limits prediction of tolerance to PEG-containing mRNA COVID vaccines”
por: Picard, Matthieu, et al.
Publicado: (2022)

The impact of inhaled corticosteroid on SARS-CoV2 infection
por: Lai, Chih-Cheng
Publicado: (2021)

Reply to D. O'Reilly et al
por: Patel, Amol, et al.
Publicado: (2021)

Reply to “PEG skin testing for COVID-19 allergy”
por: Banerji, Aleena, et al.
Publicado: (2021)

Reply to “Mortality-related immune features and COVID-19”
por: Cai, Li, et al.
Publicado: (2021)

Different effect of inhaled and systemic corticosteroids on the outcome of COVID-19 among patients with asthma
por: Hsu, Chi-Kuei, et al.
Publicado: (2022)

Eosinophilia is Associated with Improved COVID-19 Outcomes in Patients Treated with Inhaled Corticosteroids
por: Strauss, Ronald, et al.
Publicado: (2022)

Reply
por: Villa, E, et al.
Publicado: (2001)

In reply:
por: Starčević Čizmarević, Nada, et al.
Publicado: (2021)

Reply to “Does asthma affect outcomes of patients with COVID-19 infections?”
por: Mahdavinia, Mahboobeh, et al.
Publicado: (2021)

Reply to “How important is the second dose of the COVID-19 mRNA vaccine?”
por: Shaker, Marcus S., et al.
Publicado: (2021)

Reply to “SARS-CoV-2 reinfection or persistence among immunodeficient patients”
por: Marcus-Mandelblit, Nufar, et al.
Publicado: (2023)

Reply to Comment by Zhang on “Exploring the Influence of Smallholders' Perceptions Regarding Water Availability on Crop Choice and Water Allocation Through Socio‐hydrological Modeling”
por: Kuil, L., et al.
Publicado: (2019)

The Authors’ Reply
por: Mallik, Sarmila, et al.
Publicado: (2012)

The authors’ reply
por: El-Kannishy, Ghada M.
Publicado: (2018)

The authors’ reply
por: Kim, Hyo Shik, et al.
Publicado: (2017)

Authors’ reply
por: Myrtennäs, Kerstin, et al.
Publicado: (2017)

The author’s reply
por: Park, Chun Soo
Publicado: (2022)

The author’s reply
por: Park, Hyung Joo
Publicado: (2022)

Reply to “The forced renaissance of telemedicine during COVID-19: A fellow-in-training's perspective”
por: Bansal, Priya, et al.
Publicado: (2021)

Reply to “Patient variability in severity of COVID-19 disease. Main suspect: vascular endothelium”
por: Ballow, Mark, et al.
Publicado: (2021)

Reply to “Benralizumab: A potential tailored treatment for life-threatening DRESS in the COVID-19 era”
por: Lang, Claudia Cécile Valérie, et al.
Publicado: (2021)

Reply to “Protective effects of eosinophils against COVID-19: More than an ACE(2) in the hole?”
por: Ferastraoaru, Denisa, et al.
Publicado: (2021)

Reply to letters regarding our paper “Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Societyˮ
por: Kapoor, Aditya, et al.
Publicado: (2020)

Reply to Crimi, C.; Cortegiani, A. Comment on “Liu et al. Application of High-Flow Nasal Cannula in COVID-19: A Narrative Review. Life 2022, 12, 1419”
por: Liu, Cheng-Wei, et al.
Publicado: (2022)

Reply to “Risk of severe COVID-19 infection in International Space Station astronauts despite routine pre-mission measures”
por: Crucian, Brian E., et al.
Publicado: (2021)

AUTHORS REPLY
por: JOOB, Beuy, et al.
Publicado: (2014)

Reply to the Comment of G. Feulner
por: Weber, Werner
Publicado: (2011)

In Reply to: Fine Needle Aspiration
por: Ehsanbakhsh, Ali-Reza, et al.
Publicado: (2014)

Reply to the Comment by Littlechild and Isupov
por: Willetts, Andrew, et al.
Publicado: (2017)

Reply: Request for clarification on symptom assessment methodology in high‐risk population colonoscopy study
por: Zhang, Mingqing, et al.
Publicado: (2023)

Reply to “The Carotid Sinus as a Viscometer”
por: Lee, Ui Yun, et al.
Publicado: (2020)

Reply to ‘Management of noncompaction requires optimisation’
por: Gurunathan, Sothinathan, et al.
Publicado: (2019)

Reply to Kalfert, D. Comment on “Zwierz et al. The Long-Term Effects of 12-Week Intranasal Steroid Therapy on Adenoid Size, Its Mucus Coverage and Otitis Media with Effusion: A Cohort Study in Preschool Children. J. Clin. Med. 2022, 11, 507”
por: Zwierz, Aleksander
Publicado: (2022)

Reply to Akça, B.; Bilotta, F. Time and Type of Administered Fluids during Cesarean Section Might Not Matter for Hemodynamic Outcomes, but There Are Significant Patient Safety Concerns Regarding Colloid Use in Parturients. Comment on “Theodoraki et al. Colloid Preload versus Crystalloid Co-Load in the Setting of Norepinephrine Infusion during Cesarean Section: Time and Type of Administered Fluids Do Not Matter. J. Clin. Med. 2023, 12, 1333”
por: Theodoraki, Kassiani, et al.
Publicado: (2023)

Reply to correspondence ‘Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a “stochastic” process’ by Gonzalez et al., Retrovirology 2017
por: Oberle, Corinna S., et al.
Publicado: (2017)

The Slopes Remain the Same: Reply to Wolfe (2016)
por: Kristjánsson, Árni
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bs68vahgstmrfvcq8golib0r3i